Quality Comes First EN Sorry, your browser doesn't support embedded videos. Pharmaceuticals HOME PHARMACEUTICALS/GASTROINTESTINAL DISORDERS MENU Gastrointestinal disorders Menarini Group entered the gastroenterological therapeutic area in late ’60s with the discover and the development of a treatment for Irritable Bowel Syndrome (IBS). Later, in the early '80s enriched its portfolio with an anti-secretory drug that represented a milestone in the therapy of acid-related diseases. The Company has thus followed and sustained the fertile Italian gastroenterological research into mechanisms regulating acid secretion and inducing acid-related diseases, up to the latest discoveries, which show the involvement of Helicobacter Pylori in the pathogenesis of peptic ulcer. PEPTIC ULCER Peptic ulcer, located in the stomach or in the duodenum, is the consequence of an inflammation/erosion of the mucous membrane of these organs. It is an acid-related disease and is characterised by gastric pain and burning sensation of the stomach. It is nowadays firmly established that in more than 90% of duodenal ulcers and up to 80% of gastric ulcers, a germ called Helicobacter Pylori (HP) causes the inflammation. The non-elimination of this germ is a cause of recurrence of the disease. Moreover, HP chronic infection is strongly associated to some types of lymphoma. GASTROESOPHAGEAL REFLUX DISEASE It is estimated that 10-20% of the general population suffers from gastroesophageal reflux disease (GERD). This disease causes intense burning located behind the sternum (retrosternal pyrosis), often accentuated by the bending of the torso and accompanied by pain and acid regurgitation. Other times, the disease has atypical (extra-esophageal) manifestations, as for example, cough and laryngitis. Esophageal mucosa is particularly sensitive to acid; when the frequency and intensity of reflux takes on pathological significance over time, inflammation can produce irreversible damage to the esophagus, as erosions and small ulcers and development of precancerous lesions (Barrett's esophagus). IRRITABLE BOWEL SYNDROME IBS is one of the most frequent intestinal disorders with an incidence up to 15-20% in the general population. It is a "functional" disease, meaning an alteration in intestinal functioning, and occurs more frequently in women than in men. It is characterized by abdominal pain and swelling, alteration in defecation (constipation, diarrhoea or the alternation of the two). Pain may be continuous or recurrent (colic) and has varying intensities. Often in the same patient, abdominal pain may assume different characteristics, also in relation to precipitant factors (food, anxiety, etc.). ULCERATIVE COLITIS Ulcerative colitis (UC) is one of the major types of inflammatory bowel disease (IBD) that primarily affects the large bowel (colon) or the rectum. While the main causes of this inflammation are still unknown, the disease appears to be multifactorial and polygenic. The main clinical symptoms are diarrhoea, often with blood and mucus, and abdominal pain. Up to 35% of cases may have extra-intestinal symptoms such as joint pains and dermatological manifestations. The disease is characterized by acute episodes followed by periods of remission, during which it is clinically silent. The frequency of symptomatic episodes may vary from one or two attacks per year, to several episodes that reduce the period of well-being. If not well-cared, chronic inflammation can lead to irreversible intestinal disorders and possible development of cancerous lesions. Contact Us Terms and conditions Data Privacy Sitemap Pharmacovigilance Cookie Setting Follow Us A.Menarini Industrie Farmaceutiche Riunite S.r.l. VAT number and registration number in the Company House: 00395270481 Office of the Companies House: Florence Share Capital: € 150.000.0000 I.V. © 2021 The Menarini Group - All rights reserved SHARE ON Facebook Twitter SCROLL TO TOP ABOUT US EXECUTIVE TEAM OUR HISTORY OUR COMMITMENT TO SCIENCE OUR ROOTS SUSTAINABILITY Our Values Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history. READ MORE KEY AREAS GASTROINTESTINAL DISORDERS PAIN MEN'S HEALTH LIFESTYLE OTCS VITAMINS, MINERALS & SUPPLEMENTS Oncology OUR MANIFESTO AND VISION BPDCN HEMATOLOGIC MALIGNANCIES (CD123) ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA BREAST CANCER COLORECTAL CANCERS Are you looking for a specific product? SEARCH A PRODUCT INNOVATION & RESEARCH READ MORE PARTNERING COLLABORATION WITH STRATEGIC PARTNERS DERMA - AESTHETIC MEDICINE Share Your Innovative Idea Our corporate dedicated Business Development team is committed to assess and explore innovative new opportunities. CONTACT US RESPONSIBILITY MENARINI AGAINST COVID-19 Our Values Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history. READ MORE NEWS & MORE INTERNATIONAL FAIR PLAY MENARINI AWARD Menarini Blog Discover our stories from all over the world READ MORE FOLLOW US CAREERS Available positions on Linkedin Menarini employees make all the difference, every day. FOLLOW US ON LINKEDIN COUNTRIES Choose an area Main Locations Manufacturing Sites Research Centers Local Offices BROWSE ON MAP Our headquarter A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771 CONTACT US Careers In Menarini I want to report a problem Report a problem with a product or an adverse drug reaction Report a concern related to a code of conduct violation Issues with Menarini's Website or Apps Our website uses cookies, including third party cookies. In addition to Strictly necessary cookies that are essential to browse the website, the site features Functional cookies that ensure you make the most of your browsing experience, Performance cookies, that perform aggregate statistics on the website usage, as well as Targeting cookies that automatically tailor on-line ads on the preferences you expressed while browsing this or other websites. Should you wish to receive more information click on the Cookie Policy. To inhibit Functional cookies, Performance cookies, Targeting cookies and/or cookies of specific third parties click on MORE OPTIONS. By clicking I ACCEPT you will be accepting all the mentioned types of cookies. I ACCEPT MORE OPTIONS